Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC).

7077 Background: NGR-hTNF, a selective vascular targeting agent, improves the intratumoral doxorubicin penetration by normalizing tumor vasculature and decreasing tumor interstitial fluid pressure. A phase I trial previously selected NGR-hTNF 0.8 µg/m2 + doxorubicin (D) 75 mg/m2 for further testing. METHODS SCLC pts relapsing after a platinum-based… CONTINUE READING